N/A N=37 a/LCI-OCT Pilot in Esophagus
Barrett Esophagus
Primary: Percentage of Correctly Identified Positive (Dysplastic) Biopsies — 100.0 percentage of correct identifications
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=304 An Evaluation of the Efficacy and Safety of CSF-1 in the Temporary Correction of Presbyopia (NEAR-2)
Presbyopia
Primary: Percentage of Subjects With a ≥ 3-line Gain in BDCVA (Best Distance-Corrected Visual Acuity) at 40cm and no Loss in BDCVA ≥ 5 Letters at 4m on Day 8, 1 Hour Post-Dose 1…
N/A N=100 Analysis of Competitive Posterior Cruciate Retaining (PCR) and Posterior Stabilized (PS) Total Knee Arthroplasty (TKA)
Knee Osteoarthritis · Total Knee Arthroplasty · Knee
Primary: Medial AP Translations, in mm, During Deep Knee Bend (DKB) Activity — 4.2; -0.4; -0.5; -3.3 millimeters
Phase 3 N=97 Study of Efficacy and Safety of Twice Daily Oral LNP023 in Adult PNH Patients With Residual Anemia Despite Anti-C5 Antibody Treatment
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Primary: Marginal Proportion (Expressed as Percentages) of Participants With Sustained Increase in Hemoglobin Levels From Baseline of ≥ 2 g/dL in the Absence of Red Blood Cell…
Phase 3 N=1,421 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Pneumococcal Vaccine-Naïve Adults 60 Years of Age and Older in Japan, Korea, and Taiwan
Pneumococcal Disease
Primary: Percentage of Participants With Prompted Local Reactions Within 10 Days After Vaccination 1 (20vPnC or 13vPnC) — 12.4; 9.7; 6.2; 4.5 percentage of participants
N/A N=41 Clinical Evaluation of Two Daily Disposable Lenses in Sphere Design
Ametropia
Primary: Lens Fit Acceptance — 3.51; 3.68 score on a scale
Phase 3 N=134 Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients (BMN 270-301)
Hemophilia A
Primary: Change From Baseline in Annualized Number of Bleeding Episodes Irrespective of Exogenous FVIII Replacement Treatment [Annualized Bleeding Rate (ABR) for All Bleeds] in…
Phase 4 N=40 Optimal Care of Complicated Appendicitis
Appendicitis · Perforated Appendicitis · Ruptured Appendicitis
Primary: Overall Cost of Care
Phase 2 N=38 A Study of LY3451838 in Participants With Migraine
Migraine
Primary: Change From Baseline in the Number of Monthly Migraine Headache Days During 1-Month — -3.8; -2.7 migraine days per month
Phase 2 N=13 Opioid Modulation and Neural Reward Activation in Healthy Adults
Alcohol Drinking · Opioid Use, Unspecified
Primary: Change in Brain Activation to Reward Between Placebo and Active Medication — 0.25; 0.26 percentage signal change
Phase 1 N=61 A Study of the Safety and Effect of Repeated Administration of G-CSF on Hot Flashes in Postmenopausal Women
Postmenopausal Symptoms
Primary: Number of Participants With Adverse Events — 24; 20; 12; 10 Participants
N/A N=23 OsciPulse Device for the Prevention of VTE
Venous Thromboembolism · Deep Vein Thrombosis · Pulmonary Thromboembolisms
Primary: Part 1 - Subject's Response to Tolerability Questionnaire — 3; 0; 0; 0 Participants
Phase 2 N=12 Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell Lymphomas
Non-Hodgkin Lymphoma · Lymphoma · Diffuse Large B-Cell Lymphoma
Primary: Best Overall Response Rate of Pembrolizumab in Participants With Relapsed/Refractory Gray-zone Lymphomas (GZL) and Extra-nodal Diffuse Large B-cell Lymphomas (DLBCL)…
N/A N=1,396 Quality of Life in Chronic Obstructive Pulmonary Disease (COPD) Patients After Switching to Tiotropium Plus Olodaterol Fixed Dose Combination in Greece
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in Patients' Quality of Life (QoL) According to the Total Score of COPD Assessment Test (CAT) at Month 3 — 18.41; -5.25 Score on a scale
Phase 2 N=33 N-Acetyl-L-Leucine for Niemann-Pick Disease, Type C (NPC)
Niemann-Pick Disease, Type C
Primary: Clinical Impression of Change in Severity (CI-CS) [Fields et al 2021] — 0.86 score on a scale — p=0.029